Brain+ and Biogen preparing for commercialization in Germany, the #1 EU market for digital therapeutics
Brain+ has been selected to Biogen’s and EIT Health’s exclusive Neurotech-prize program. This will give additional momentum to the preparations for launch of Brain+’s first dementia product on the German market in 2023. The German market is a global ‘reference’ market for Digital Therapeutics (DTx) products and succeeding here creates a strong base for global expansion.· The program will give Brain+ direct access to world-class mentors and experts on the German market and provide valuable support to the development of an effective business model and go-to-market strategy for the company’s